We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Abbreviated versus Standard Duration of DAPT after PCI: A Systematic Review and Network Meta-analysis.
- Authors
Park, Dae Yong; An, Seokyung; Kumar, Ashish; Malhotra, Saurabh; Jolly, Neeraj; Kaur, Amandeep; Kattoor, Ajoe; Doukky, Rami; Kalra, Ankur; Vij, Aviral
- Abstract
Background: Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) is typically continued for 6–12 months depending on clinical presentation. Recent studies have evaluated the safety of shorter durations of DAPT across stable and unstable coronary syndrome but are limited by smaller patient pools and varying indications. Methods: The present study performed a systematic review and network meta-analysis comparing abbreviated (1–3 months) with standard (6–12 months) duration of DAPT. Both conventional and frequentist network meta-analyses with a random-effects model were conducted. Results: Seventeen randomized controlled trials, nine of which included 1–3 months of DAPT, were selected. The risks of any bleeding (RR 0.68, 95% CI 0.54–0.85), major bleeding (RR 0.66, 95% CI 0.50–0.86), and net adverse clinical events (NACE) (RR 0.87, 95% CI 0.76–0.99) were lower with abbreviated (1–3 months) than standard-term (6–12 months) DAPT. No significant differences in the risk of myocardial infarction (RR 1.02, 95% CI 0.87–1.18), definite or probable stent thrombosis (RR 1.11, 95% CI 0.83–1.50), and major adverse cardiac events (MACE) (RR 0.96, 95% CI 0.86–1.06) were observed. Network meta-analysis demonstrated lower risk of any bleeding, major bleeding, and NACE with shorter durations of DAPT compared with 12 months. Risks of definite or probable stent thrombosis, myocardial infarction, and MACE were not significantly different. Conclusion: The results support the growing body of evidence that abbreviated duration (1–3 months) of DAPT may be considered to reduce the risk of bleeding without any differences in myocardial infarction, stent thrombosis, or MACE.
- Subjects
MYOCARDIAL infarction risk factors; SURGICAL complication risk factors; HEMORRHAGE risk factors; PREVENTION of surgical complications; HEMORRHAGE prevention; THROMBOSIS risk factors; PERCUTANEOUS coronary intervention; COMBINATION drug therapy; META-analysis; CONFIDENCE intervals; DRUG-eluting stents; TIME; SYSTEMATIC reviews; MAJOR adverse cardiovascular events; POSTOPERATIVE care; TREATMENT duration; RISK assessment; PLATELET aggregation inhibitors; DESCRIPTIVE statistics; ODDS ratio; PATIENT safety; DISEASE risk factors
- Publication
American Journal of Cardiovascular Drugs, 2022, Vol 22, Issue 6, p633
- ISSN
1175-3277
- Publication type
Article
- DOI
10.1007/s40256-022-00541-w